Vericel (VCEL) Income towards Parent Company (2010 - 2026)
Vericel (VCEL) reported Income towards Parent Company of -$6.8 million for Q1 2026, up 41.85% on a YoY basis from -$4.8 million in Q1 2025, and down 128.33% sequentially from $24.1 million in Q4 2025.
Vericel (VCEL) Income towards Parent Company (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 17 years of Income towards Parent Company data on file, last reported at -$6.8 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company rose 41.85% year-over-year to -$6.8 million; the trailing twelve-month figure through Mar 2026 stood at $20.9 million (up 946.8% YoY), and the FY2025 full-year result was $16.5 million, up 59.41% from the prior year.
- Income towards Parent Company retreated to -$6.8 million in Q1 2026, from $24.1 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $24.1 million in Q4 2025 to a low of -$55.9 million in Q2 2023.
- A 5-year average of -$3.1 million and a median of -$4.3 million in 2024 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company slumped 523.47% in 2023 and surged 614.21% in 2025, its largest moves.
- Tracing VCEL's Income towards Parent Company over 5 years: stood at $5.9 million in 2022, then surged by 119.4% to $13.0 million in 2023, then soared by 52.44% to $19.8 million in 2024, then increased by 21.87% to $24.1 million in 2025, then tumbled by 128.33% to -$6.8 million in 2026.
- Business Quant data shows VCEL's Income towards Parent Company at -$6.8 million in Q1 2026, $24.1 million in Q4 2025, and $4.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.84 Mn |
| Dec 31, 2025 | 24.14 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | -997,000.00 |
| Mar 31, 2025 | -11.76 Mn |
| Dec 31, 2024 | 19.81 Mn |
| Sep 30, 2024 | -901,000.00 |
| Jun 30, 2024 | -5.15 Mn |
| Mar 31, 2024 | -4.33 Mn |
| Dec 31, 2023 | 12.99 Mn |
| Sep 30, 2023 | -3.66 Mn |
| Jun 30, 2023 | -55.88 Mn |
| Mar 31, 2023 | -7.96 Mn |
| Dec 31, 2022 | 5.92 Mn |
| Sep 30, 2022 | -6.58 Mn |
| Jun 30, 2022 | -8.96 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | 4.54 Mn |
| Sep 30, 2021 | -4.93 Mn |
| Jun 30, 2021 | -3.79 Mn |